Literature DB >> 6145596

Single and multiple dose kinetics of clobazam, and clinical effects during multiple dosage.

H R Ochs, D J Greenblatt, M Lüttkenhorst, B Verburg-Ochs.   

Abstract

Sixteen healthy volunteers, aged 19 to 62 years, took a single 20-mg oral dose of clobazam and the serum concentrations of clobazam and desmethylclobazam were measured for the following 7 days. The mean kinetic variables for clobazam were: volume of distribution 1.31/kg, elimination half-life 24h, total clearance 0.47 ml/min/kg. 13 of the volunteers then took clobazam 5 mg twice daily for 22 consecutive days. Serum concentrations were measured during and after this period. Both clobazam and desmethylclobazam showed slow and extensive accumulation, their steady-state kinetics being entirely consistent with those observed after single doses. Elimination of both compounds after termination of treatment was equally slow. Clinical self-rating of morning sedation indicated a significant increase over baseline in subjective perception of sedation during the treatment period, and this effect persisted into the washout period. However, sedation did not increase in parallel with accumulating levels of clobazam and desmethylclobazam, probably due to functional adaptation or tolerance.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6145596     DOI: 10.1007/bf00542148

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  18 in total

1.  Sleeping pills, insomnia and medical practice.

Authors:  F Solomon; C C White; D L Parron; W B Mendelson
Journal:  N Engl J Med       Date:  1979-04-05       Impact factor: 91.245

2.  Pharmacokinetics and bioavailability of intravenous, intramuscular, and oral lorazepam in humans.

Authors:  D J Greenblatt; R I Shader; K Franke; D S MacLaughlin; J S Harmatz; M D Allen; A Werner; E Woo
Journal:  J Pharm Sci       Date:  1979-01       Impact factor: 3.534

3.  Pharmacokinetics of single and multiple doses of clobazam in humans.

Authors:  W Rupp; M Badian; O Christ; P Hajdú; R D Kulkarni; K Taeuber; M Uihlein; R Bender; O Vanderbeke
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

4.  Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide.

Authors:  R I Shader; A Georgotas; D J Greenblatt; J S Harmatz; M D Allen
Journal:  Clin Pharmacol Ther       Date:  1978-09       Impact factor: 6.875

5.  Electron-capture GLC determination of clobazam and desmethylclobazam in plasma.

Authors:  D J Greenblatt
Journal:  J Pharm Sci       Date:  1980-11       Impact factor: 3.534

6.  Reduced single-dose clearance of clobazam in elderly men predicts increased multiple-dose accumulation.

Authors:  D J Greenblatt; M Divoll; S K Puri; I Ho; M A Zinny; R I Shader
Journal:  Clin Pharmacokinet       Date:  1983 Jan-Feb       Impact factor: 6.447

7.  Pharmacokinetics and bioavailability of intravenous, oral, and rectal nitrazepam in humans.

Authors:  R Jochemsen; J J Hogendoorn; J Dingemanse; J Hermans; J K Boeijinga; D D Breimer
Journal:  J Pharmacokinet Biopharm       Date:  1982-06

8.  Absorption of oral and intramuscular chlordiazepoxide.

Authors:  D J Greenblatt; R I Shader; S M MacLeod; E M Sellers; K Franke; H G Giles
Journal:  Eur J Clin Pharmacol       Date:  1978-06-19       Impact factor: 2.953

9.  Absolute bioavailability of oral and intramuscular diazepam: effects of age and sex.

Authors:  M Divoll; D J Greenblatt; H R Ochs; R I Shader
Journal:  Anesth Analg       Date:  1983-01       Impact factor: 5.108

10.  Absorption rate, blood concentrations, and early response to oral chlordiazepoxide.

Authors:  D J Greenblatt; R I Shader; J S Harmatz; K Franke; J Koch-Weser
Journal:  Am J Psychiatry       Date:  1977-05       Impact factor: 18.112

View more
  8 in total

Review 1.  Clobazam therapeutic drug monitoring: a comprehensive review of the literature with proposals to improve future studies.

Authors:  Jose de Leon; Edoardo Spina; Francisco J Diaz
Journal:  Ther Drug Monit       Date:  2013-02       Impact factor: 3.681

2.  Influence of dosing regimen on alprazolam and metabolite serum concentrations and tolerance to sedative and psychomotor effects.

Authors:  R B Smith; P D Kroboth
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

3.  Impact of cytochrome P450 inducers with or without inhibitors on the serum clobazam level in patients with antiepileptic polypharmacy.

Authors:  Yoshiaki Yamamoto; Yukitoshi Takahashi; Katsumi Imai; Masaaki Takahashi; Masahiko Nakai; Yushi Inoue; Yoshiyuki Kagawa
Journal:  Eur J Clin Pharmacol       Date:  2014-07-22       Impact factor: 2.953

Review 4.  Biomarkers for the effects of benzodiazepines in healthy volunteers.

Authors:  S J de Visser; J P van der Post; P P de Waal; F Cornet; A F Cohen; J M A van Gerven
Journal:  Br J Clin Pharmacol       Date:  2003-01       Impact factor: 4.335

5.  Determinants of benzodiazepine brain uptake: lipophilicity versus binding affinity.

Authors:  R M Arendt; D J Greenblatt; D C Liebisch; M D Luu; S M Paul
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

6.  A physiologically based pharmacokinetic model for clobazam and stiripentol in adults and children.

Authors:  Kayode Ogungbenro; Leon Aarons
Journal:  Pharm Res       Date:  2014-07-23       Impact factor: 4.200

7.  A Phase 1, Open-Label, Pharmacokinetic Trial to Investigate Possible Drug-Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects.

Authors:  Gilmour Morrison; Julie Crockett; Graham Blakey; Kenneth Sommerville
Journal:  Clin Pharmacol Drug Dev       Date:  2019-02-21

Review 8.  A Comprehensive Overview of the Clinical Pharmacokinetics of Clobazam.

Authors:  Dwain Tolbert; Frank Larsen
Journal:  J Clin Pharmacol       Date:  2018-10-04       Impact factor: 3.126

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.